-
Mashup Score: 1Arun Krishna, AstraZeneca, on Results from the LAURA Trial: Tagrisso Effectively Combats NSCLC | Docwire News - 2 month(s) ago
Arun Krishna, of AstraZeneca, talks about the LAURA Phase III trial, which assessed Tagrisso in NSCLC patients.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
Arun Krishna, VP, Head of US Lung Cancer Franchise at @AstraZeneca discusses the importance of the new #Tagrisso data yielded in the LAURA study on #NSCLC Watch Now: https://t.co/7SASWW7o8z https://t.co/QKdlErc85d